Drug Profile
Asunercept companion diagnostic - Amoy Diagnostics/CANbridge Pharmaceuticals
Alternative Names: Asunercept companion diagnostic - CANbridge Pharmaceuticals/Amoy Diagnostics; CAN 008 companion diagnostic - Amoy Diagnostics/CANbridge Pharmaceuticals; CAN 008 companion diagnostic - CANbridge Pharmaceuticals/Amoy DiagnosticsLatest Information Update: 28 Jun 2021
Price :
$50
*
At a glance
- Originator Amoy Diagnostics
- Developer Amoy Diagnostics; CANbridge Pharmaceuticals
- Class Diagnostic agents
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Unspecified
Most Recent Events
- 28 Jun 2021 No recent reports of development identified for research development in Unspecified(Diagnosis) in China
- 16 May 2017 Early research in Undefined indication (Diagnosis) in China
- 16 May 2017 CANbridge Life Sciences and Amoy Diagnostics collaborate to develop companion diagnostics for asunercept